文献速递造血干细胞移植与细胞治疗

移植后环磷酰胺为基础的移植物抗宿主病预防在70岁及以上患者中的影响:BMT CTN 1703研究更新

Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703.
PubMed 文献 · Blood Adv · 2025-01-01

BMT CTN 1703试验将接受减低强度预处理异基因造血细胞移植的血液恶性肿瘤成人随机分配至移植后环磷酰胺+吗替麦考酚酯+他克莫司(PTCy)组或他克莫司+甲氨蝶呤(Tac/MTX)组预防移植物抗宿主病。本分析纳入96例70岁及以上患者,PTCy组无移植物抗宿主病无复发生存(GRFS)率为67.1%,Tac/MTX组为29.5%(P=0.001),1年调整生存率分别为94.3%和60.2%(P=0.001)。

要点

  • 70岁及以上患者中,PTCy组GRFS率67.1% vs Tac/MTX组29.5%(P=0.001),PTCy维持优效。
  • PTCy组1年调整生存率94.3% vs Tac/MTX组60.2%(P=0.001),差异显著。
  • PTCy组1年非复发死亡率更低,移植物抗宿主病控制及无免疫抑制生存改善。

核心结论

  • 以PTCy为基础的移植物抗宿主病预防应被视为老年成人的标准预防方案。
  • 鉴于PTCy方案非复发死亡率低且生存结局优异,应更广泛地考虑为老年患者、尤其是70岁及以上患者进行异基因造血细胞移植。

研究设计与样本

  • BMT CTN 1703试验(NCT03959241)将接受减低强度预处理后异基因造血细胞移植的血液恶性肿瘤成人随机分配至PTCy方案组或Tac/MTX方案组进行移植物抗宿主病预防。
  • 本分析聚焦该试验中96例70岁及以上患者,分析其结局。

主要发现

  • PTCy组主要终点GRFS率为67.1%,Tac/MTX组为29.5%(P=0.001)。
  • PTCy组1年非复发死亡率更低,移植物抗宿主病控制及无免疫抑制生存改善。
  • PTCy组复发/进展率更低。
  • PTCy组1年调整生存率为94.3%,Tac/MTX组为60.2%(P=0.001)。

临床怎么用

  • 作者认为,以PTCy为基础的移植物抗宿主病预防应被视为老年成人的标准预防方案。
  • 作者认为,鉴于非复发死亡率低且生存结局优异,应更广泛地考虑为老年患者、尤其是70岁及以上患者进行异基因造血细胞移植。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplant (allo-HCT) is underutilized in adults aged ≥70 years. Morbidity, often driven by graft-versus-host disease (GVHD), is considered a major barrier to its use. The BMT CTN 1703 trial (ClinicalTrials.gov identifier: NCT03959241) randomly assigned adults with hematologic malignancies undergoing allo-HCT after reduced intensity conditioning to receive either posttransplant cyclophosphamide, mycophenolate mofetil, and tacrolimus (PTCy) or tacrolimus and methotrexate (Tac/MTX) for GVHD prophylaxis. Overall study results revealed superior GVHD-free, relapse-free survival (GRFS) with PTCy-based prophylaxis. This analysis explored the impact of PTCy in patients aged ≥70 years enrolled in BMT CTN 1703. We analyzed outcomes for 96 patients aged ≥70 years. PTCy maintained superiority for the primary end point with a GRFS rate of 67.1% compared with 29.5% with Tac/MTX (P = .001). GVHD control and improved immunosuppression-free survival contributed to a lower 1-year nonrelapse mortality (NRM) with PTCy. Furthermore, lower rates of relapse/progression were observed with PTCy, altogether resulting in significantly improved adjusted 1-year survival with PTCy at 94.3% vs 60.2% with Tac/MTX (P = .001). PTCy-based GVHD prophylaxis should be considered standard prophylaxis for older adults. Given low rates of NRM and excellent survival outcomes with this approach, there should be greater consideration for allo-HCT in older patients, particularly patients aged ≥70 years. This trial was registered at www.ClinicalTrials.gov as #NCT03959241.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Abedin S, Martens MJ, Bolaños-Meade J, et al. Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703. Blood Adv. 2025. PMID: 40305657. doi:10.1182/bloodadvances.2025015964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。